These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 11560981)
1. Tamoxifen for patients with estrogen receptor-negative breast cancer. Swain SM J Clin Oncol; 2001 Sep; 19(18 Suppl):93S-97S. PubMed ID: 11560981 [No Abstract] [Full Text] [Related]
2. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related]
3. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971 [TBL] [Abstract][Full Text] [Related]
4. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
5. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L; Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242 [TBL] [Abstract][Full Text] [Related]
7. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118 [TBL] [Abstract][Full Text] [Related]
8. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group. Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M; J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087 [TBL] [Abstract][Full Text] [Related]
9. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
11. [The effect of long-term tamoxifen therapy on the occurrence of contralateral primary breast cancer]. Xing B; Huang X; Wang Y Zhonghua Zhong Liu Za Zhi; 1996 Mar; 18(2):143-5. PubMed ID: 9206051 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
13. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer. Lash TL; Gurwitz JH; Silliman RA J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369 [TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related]
15. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Lundin AC; Söderkvist P; Eriksson B; Bergman-Jungeström M; Wingren S Cancer Res; 1999 May; 59(10):2332-4. PubMed ID: 10344739 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
17. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Hillner BE Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322 [TBL] [Abstract][Full Text] [Related]
18. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044 [TBL] [Abstract][Full Text] [Related]
19. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen. Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896 [TBL] [Abstract][Full Text] [Related]
20. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients]. Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]